Experimental chemotherapy studies: intercomparison of assays

Area of Science:

• Oncology
• Pharmacology
• Experimental Therapeutics

Background:

• Chemotherapy response is typically assessed by cell survival and tumor growth delay.
• Both endpoints present interpretation challenges due to biological factors.
• Timing of measurements and host-tumor interactions significantly impact results.

Purpose of the Study:

• To analyze complicating factors in measuring chemotherapy response.
• To investigate the influence of timing and host factors on endpoint interpretation.
• To present new data on chemotherapy response in specific experimental tumor models.

Main Methods:

• Utilizing experimental tumor systems to measure cell survival and tumor growth delay.
• Analyzing the impact of measurement time points on cell survival data.
• Considering host-specific effects, including immunogenicity, on tumor growth delay.
• Evaluating the cytostatic and cytotoxic effects of chemotherapeutic agents.
• Presenting data for RIF-1 tumors and EMT6/Ca/VJAC multicellular tumor spheroids.

Main Results:

• Cell survival measurements are sensitive to the time of assessment post-drug administration.
• Tumor growth delay can be influenced by host responses and regenerative proliferation rates.
• Different cytotoxic drugs can induce varying growth delays for equivalent cell killing.
• Some agents exhibit cytostatic effects, causing growth delay without significant cell killing.

Conclusions:

• Accurate interpretation of chemotherapy response requires careful consideration of measurement timing and biological factors.
• Host-mediated effects and regenerative proliferation are critical determinants of tumor growth delay.
• Distinguishing between cytostatic and cytotoxic effects is essential for understanding treatment outcomes.
• The presented data offer insights into chemotherapy response in RIF-1 tumors and EMT6/Ca/VJAC spheroids.